GURUFOCUS.COM » STOCK LIST » Real Estate » REITs » BioMed Realty Trust Inc (NYSE:BMR) » Definitions » EBITDA

BioMed Realty Trust (BioMed Realty Trust) EBITDA : $560.9 Mil (TTM As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is BioMed Realty Trust EBITDA?

BioMed Realty Trust's EBITDA for the three months ended in Sep. 2015 was $114.7 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 was $560.9 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

BioMed Realty Trust's EBITDA per Share for the three months ended in Sep. 2015 was $0.55. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2015 was $2.58.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


BioMed Realty Trust EBITDA Historical Data

The historical data trend for BioMed Realty Trust's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMed Realty Trust EBITDA Chart

BioMed Realty Trust Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 245.05 278.83 312.67 337.79 538.54

BioMed Realty Trust Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.64 218.74 109.26 118.16 114.72

Competitive Comparison of BioMed Realty Trust's EBITDA

For the REIT - Office subindustry, BioMed Realty Trust's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMed Realty Trust's EV-to-EBITDA Distribution in the REITs Industry

For the REITs industry and Real Estate sector, BioMed Realty Trust's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioMed Realty Trust's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BioMed Realty Trust's EBITDA for the fiscal year that ended in Dec. 2014 is calculated as

BioMed Realty Trust's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2014, BioMed Realty Trust's EBITDA was $538.5 Mil.

BioMed Realty Trust's EBITDA for the quarter that ended in Sep. 2015 is calculated as

BioMed Realty Trust's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2015, BioMed Realty Trust's EBITDA was $114.7 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $560.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

BioMed Realty Trust  (NYSE:BMR) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


BioMed Realty Trust EBITDA Related Terms

Thank you for viewing the detailed overview of BioMed Realty Trust's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioMed Realty Trust (BioMed Realty Trust) Business Description

Traded in Other Exchanges
N/A
Address
BioMed Realty Trust Inc, a Maryland corporation was formed on April 30, 2004 and commenced operations on August 11, 2004, after completing its initial public offering. The Company operates as a self-administered and self-managed real estate investment trust focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry mainly through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership Its tenants mainly include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/ New Jersey. The Company faces competition from various entities for investment opportunities in properties for life science tenants, including other REITs, such as health care REITs and suburban office property REITs, pension funds, insurance companies, investment funds and companies, partnerships, and developers. The Company's properties are subject to various laws, ordinances and regulations, including regulations relating to common areas.
Executives
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Brody William R Md Phd director MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Janice L. Sears director 1100 PARK PLACE, SUITE 200, SAN MATEO CA 94403
Alan D Gold director, officer: Chairman, President and CEO 17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Gary A Kreitzer director, officer: Exec VP and Assistant Sec 17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Margaret Faye Wilson director 12836 LUNADA PLACE, SAN DIEGO CA 92128
Griffin R Kent Jr officer: President and COO 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225
Richard I Gilchrist director 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225